Access VetMed ads

📢 Freelance opportunity in Brussels Access VetMed is looking for a freelance EU Public Affairs Advisor to collaborate with us, helping the association keep a credible presence in Brussels and engage early in the policy discussions that shape access to veterinary medicines in Europe. 🔎 What the assignment involves: • Monitoring EU policy developments and flagging emerging risks and opportunities • Turning technical topics into clear political messages for decision-makers • Building relationships with the European Parliament, Commission and Council, and with partner organisations across sectors • Representing Access VetMed at relevant Brussels-based events and policy debates 👤 The profile we have in mind. • A politically aware professional who knows how the EU works • Communicates clearly in English and enjoys building trust with members and stakeholders. • Experience in health, pharma or animal health is a plus, but not essential. 📍 Brussels-based | Freelance | Part-time, flexible schedule 🗓️ Applications open until 11 December 2026 📩 Send a short motivation letter and CV to Elsa Vecino, Technical Director: [email protected] 🔗 Full details: https://lnkd.in/dPbygmMb Know someone who'd be a great fit? Please share this post 🙌 #TogetherStronger #AccessVetMed #EUAffairs #PublicAffairs #Freelance #Brussels #AnimalHealth #VeterinaryMedicines

💥 Have you explored our Bursting Myths Playbook yet? Veterinary generics are still surrounded by misconceptions. That’s why Access VetMed brought together leading stakeholders from across the animal health sector to tackle some of the most persistent myths head-on. Throughout the Bursting Myths Playbook, recognised experts address each myth with clear, evidence-based arguments, helping to separate perception from reality and to better understand the value that generic and added-value veterinary medicines bring to animal health across Europe. 👉 Click through and discover the facts behind the myths — and why it’s time to look at veterinary generics from a different perspective: https://lnkd.in/eFA7yKNS #AccessVetMed #BurstingMyths #VeterinaryMedicines #AnimalHealth #GenericMedicines #VeterinaryIndustry

🎥 How is the European generic and added-value veterinary medicines industry evolving? In this video, Access VetMed Board member Andreas Asamer, CEO of VetViva Richter GmbH, shares some of the key trends shaping our industry, based on the market update he presented at this year’s General AssemblyManager Meeting. ▶️ Watch the video to hear Andreas’ perspective on these developments and the challenges ahead. #AccessVetMed #VeterinaryMedicines #AnimalHealth #GenericMedicines #VeterinaryIndustry

🤝 Turning technical detail into practical value. Access VetMed’s work is not only about raising concerns. It is about turning member evidence into concrete regulatory influence and practical outcomes. In the last year, our activities have focused on four connected areas: 🔹 Influence through regular engagement with EU and national authorities 🔹 Burden reduction and efficiency through member evidence and market analysis 🔹 Regulatory predictability through work on QRD implementation, SPC harmonisation, generic and hybrid procedures, and PTD transparency 🔹 Future preparedness on topics such as PFAS, biosimilars, AI, and others. A stronger regulatory environment supports better access to veterinary medicines. 🐾💊 #AccessVetMed #VeterinaryMedicines #RegulatoryAffairs #AnimalHealth #EURegulation #Generics #TogetherStronger

📊 Availability matters. One of the key messages from our annual General Managers Meeting, held in Ireland last week, was the importance of maintaining and expanding access to veterinary medicines across Europe. 💪 It was also an opportunity to reflect on some encouraging developments. Our latest Access VetMed market analysis shows a net increase of 576 veterinary medicine marketing authorisations between May 2025 and May 2026, with generic and hybrid products recording the strongest growth. ✅ These figures highlight the important contribution of generic and added-value veterinary medicines to maintaining and expanding treatment options for animals across Europe. ‼️ At the same time, our latest member survey points to a growing challenge: the resources and financial investment required to comply with regulatory and pharmacovigilance obligations continue to increase year after year. This is why Access VetMed continues to advocate for a regulatory environment that supports availability, predictability and proportionality, helping generic and added-value veterinary medicines remain accessible across Europe. Because maintaining access to veterinary medicines is not only an animal health issue — it is a One Health priority. 🐾🌍💊 #AccessVetMed #VeterinaryMedicines #AnimalHealth #OneHealth #Availability #MarketAccess

🔬💊 Myth #4: “Generic veterinary medicines are not properly tested and authorised.” ❌ Myth. The reality is that generic veterinary medicines undergo a rigorous scientific assessment before they can be authorised and placed on the European market. Manufacturers must provide comprehensive evidence demonstrating the product’s quality, safety and efficacy, including proof of bioequivalence with the reference medicine. Regulatory authorities carefully evaluate this information according to the same strict European requirements applied to all veterinary medicines. 💡 Generic does not mean less tested. It means scientifically proven to deliver the same therapeutic benefits. Laiho Pauli from Medfiles, explains the rigorous evaluation and authorisation process behind every generic veterinary medicine available in Europe. A big thank you to everyone contributing to our #BurstingMyths campaign and helping us separate fact from fiction. 🎥 Watch Myth #4 and discover the facts behind the myth: https://lnkd.in/exG6MYTE #BurstingMyths #GenericVeterinaryMedicines #VeterinaryMedicines #RegulatoryScience #Bioequivalence #AnimalHealth #ScienceMatters